A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for colorectal cancer liver metastases

Liu, Wei; Song, Qingkun; Xing, Baocai

doi:10.1007/s00384-015-2246-2

Cited by 12 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Use of HAIP for adjuvant therapy after liver resection has never gained widespread acceptance despite a randomized controlled and recent meta‐analysis reporting a strong benefit . Survival outcomes from several clinical trials and case series are shown in Table .…”

Section: Discussionmentioning

confidence: 99%

“…40 Use of HAIP for adjuvant therapy after liver resection has never gained widespread acceptance despite a randomized controlled and recent meta-analysis reporting a strong benefit. 17,41 Survival outcomes from several clinical trials and case series are shown in Table 5. The patients in these trials all received adjuvant HAIP FUDR infusion, and the early trials which used HAI 5-FU are not included.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Implementation and early outcomes for a surgeon‐directed hepatic arterial infusion pump program for colorectal liver metastases

Chakedis

Beal

Sun

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

Introduction Hepatic arterial infusion pump (HAIP) therapy for colorectal liver metastases (CRLM) is beneficial in selected patients yet wide acceptance in the oncology community is lacking. Methods A surgeon‐led team implemented a HAIP program in 2012. Pumps were placed by laparotomy for CRLM and fluorodeoxyuridine was infused via HAIP every 28 days without systemic chemotherapy supervised by the operating surgeon. Results Sixty patients were treated with HAIP, either in the adjuvant setting after liver resection or ablation of CRLM in 26 (43%) patients or with the unresectable disease in 34 (57%). Perioperative complications occurred in 19 (32%) and pump‐specific complications in 14 (23%) that included intrahepatic biliary stricture in one (2%). Time to liver progression was a median 9.2 months (95% CI, 3.1‐15.3 months) in unresectable patients and liver recurrence was a median 24.7 months (2.5‐46.9 months) in the adjuvant group. Estimated 3‐year overall survival from the time of HAIP placement was 64% in the adjuvant group and 37% in the unresectable group. Sarcopenia was prevalent (48%) and was associated with a worse survival (HR 2.4, 95% CI, 1.1‐5.0). Conclusion A surgeon‐led HAIP program may achieve outcomes on par with those of experienced centers and foster strong relationships between surgical and medical oncologists.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Implementation and early outcomes for a surgeon‐directed hepatic arterial infusion pump program for colorectal liver metastases

Chakedis

Beal

Sun

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Liu et al identified nine randomized and non-randomized studies with a pooled HR for OS of 0.75 (95% CI: 0.56-0.99) in favor of HAIC. 35 However, this study included several overlapping cohorts and 5 more recent studies were not included. Additional adequately powered RCTs are needed to investigate whether HAIC can improve survival.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and meta-analysis

Buisman

Filipe

Galjart

et al. 2022

HPB

View full text Add to dashboard Cite

“…employed for the treatment of hepatic tumors [98], but some literature has also been published on its use in pancreatic cancer [9,[30][31][32][33]. The exact tumor location and its supplying arteries determine through which vessels the chemotherapeutic infusion will be delivered.…”

Section: Immunomodulation After 125 I Seed Implantationmentioning

confidence: 99%

Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy

et al. 2021

View full text Add to dashboard Cite

Purpose of Review Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive neoplasms, bearing a terrible prognosis. Stage III tumors, also known as locally advanced pancreatic cancer (LAPC), are unresectable, and current palliative chemotherapy regimens have only modestly improved survival in these patients. At this stage of disease, interventional techniques may be of value and further prolong life. The aim of this review was to explore current literature on locoregional percutaneous management for LAPC. Recent Findings Locoregional percutaneous interventional techniques such as ablation, brachytherapy, and intra-arterial chemotherapy possess cytoreductive abilities and have the potential to increase survival. In addition, recent research demonstrates the immunomodulatory capacities of these treatments. This immune response may be leveraged by combining the interventional techniques with intra-tumoral immunotherapy, possibly creating a durable anti-tumor effect. This multimodality treatment approach is currently being examined in several ongoing clinical trials. Summary The use of certain interventional techniques appears to improve survival in LAPC patients and may work synergistically when combined with immunotherapy. However, definitive conclusions can only be made when large prospective (randomized controlled) trials confirm these results.

show abstract

A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for colorectal cancer liver metastases

Abstract: Adjuvant hepatic arterial infusion improved the 5-year disease-free and overall survival rate, respectively. It should be recommended for patients with a high risk of recurrence, but these findings require prospective confirmation.

Cited by 12 publications

References 41 publications

Implementation and early outcomes for a surgeon‐directed hepatic arterial infusion pump program for colorectal liver metastases

Implementation and early outcomes for a surgeon‐directed hepatic arterial infusion pump program for colorectal liver metastases

Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and meta-analysis

Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy

Contact Info

Product

Resources

About